Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group | Zendy

Rob Pieters | Zendy; Hester de GrootKruseman | Zendy; Vincent van der Velden | Zendy; Marta Fiocco | Zendy; Henk van den Berg | Zendy; Evelien de Bont | Zendy; R. Maarten Egeler | Zendy; Peter M. Hoogerbrugge | Zendy; Gertjan J.L. Kaspers | Zendy; C. Ellen van der Schoot | Zendy; Valérie de Haas | Zendy; Jacques J. M. van Dongen | Zendy

Open Access

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

Author(s) -

Rob Pieters,

Hester de GrootKruseman,

Vincent van der Velden,

Marta Fiocco,

Henk van den Berg,

Evelien de Bont,

R. Maarten Egeler,

Peter M. Hoogerbrugge,

Gertjan J.L. Kaspers,

C. Ellen van der Schoot,

Valérie de Haas,

Jacques J. M. van Dongen

Publication year - 2016

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2015.64.6364

Subject(s) - medicine , cumulative incidence , minimal residual disease , vincristine , chemotherapy , hematopoietic stem cell transplantation , acute lymphocytic leukemia , incidence (geometry) , transplantation , pediatrics , leukemia , oncology , surgery , lymphoblastic leukemia , cyclophosphamide , physics , optics

Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying chemotherapy for all patients. Minimal residual disease (MRD) levels during the first months predict outcome and may select patients for therapy reduction or intensification.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research